Maynard Um
-
-
-
-
-
-
-
FDA accepts Teva's drug application for Tourette syndrome therapy in children
-
-
-
-
-
-
-
UBS Reiterates Buy Rating on Teva Pharma (TEVA) as Pipeline Opportunities Broaden
-
-
-
-
-
-
-
Teva Pharma (TEVA) PT Lowered to $40 at BofA Securities
-
-
-
-
-
-
-
Barclays on Teva Pharma (TEVA) Amid 1.5pct Drop: '<$30 as a buy-the-dip oppty'
-
-
-
-
-
-
-
This stock looks cheap vs large-cap biopharma: Jefferies
-
-
-
-
-
-
-
Teva Pharma (TEVA) Tops Q4 EPS by 31c, Beats on Revenue; Offers FY26 Revenue Guidance
-
-
-
-
-
-
-
Teva Pharma (TEVA) call put ratio 6.3 calls to 1 put into the annual J.P. Morgan Healthcare Conference
-
449,265 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

